Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma

Cancer

Volumn 98, Issue 3, 2003, Pages 484-495

  Meyerhardt, Jeffrey A ^a   Catalano, Paul J ^a,b   Haller, Daniel G ^c   Mayer, Robert J ^a   Benson III, Al B ^d   Macdonald, John S ^e   Fuchs, Charles S ^a,f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Statistical Center   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Lung Transplant Unit   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adjuvant chemotherapy; Body mass index; Colon carcinoma; Obesity; Treatment related toxicity

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

ADULT; AGED; ARTICLE; BODY MASS; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; UNITED STATES; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BODY WEIGHT; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LEVAMISOLE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OBESITY; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 0037962010     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11544     Document Type: Article

References (66)

1. Dietz AT, Newcomb PA, Marcus PM, Storer BE. The association of body size and large bowel cancer risk in Wisconsin (United States) women. Cancer Causes Control. 1995;6:30-36.
2. Whittemore AS, Wu-Williams AH, Lee M, et al. Diet, physical activity, and colorectal cancer among Chinese in North America and China. J Natl Cancer Inst. 1990;82:915-926.
3. Kune GA, Kune S, Watson LF. Body weight and physical activity as predictors of colorectal cancer risk. Nutr Cancer. 1990;13:9-17.
4. West DW, Slattery ML, Robison LM, et al. Dietary intake and colon cancer: sex- and anatomic site-specific associations. Am J Epidemiol. 1989;130:883-894.
5. Lee IM, Paffenbarger RS Jr. Quetelet's index and risk of colon cancer in college alumni. J Natl Cancer Inst. 1992;84:1326-1331.
6. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995;122:327-334.
7. Le Marchand L, Wilkins LR, Mi MP. Obesity in youth and middle age and risk of colorectal cancer in men. Cancer Causes Control. 1992;3:349-354.
8. Chyou PH, Nomura AM, Stemmermann GN. A prospective study of colon and rectal cancer among Hawaii Japanese men. Ann Epidemiol. 1996;6:276-282.
9. Bostick RM, Potter JD, Kushi LH, et al. Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). Cancer Causes Control. 1994;5:38-52.
10. Martinez ME, Giovannucci E, Spiegelman D, Hunter DJ, Willett WC, Colditz GA. Leisure-time physical activity, body size, and colon cancer in women. Nurses' Health Study Research Group. J Natl Cancer Inst. 1997;89:948-955.
11. Ford ES. Body mass index and colon cancer in a national sample of adult US men and women. Am J Epidemiol. 1999;150:390-398.
12. Neugut AI, Lee WC, Garbowski GC, et al. Obesity and colorectal adenomatous polyps. J Natl Cancer Inst. 1991;83:359-361.
13. Shinchi K, Kono S, Honjo S, et al. Obesity and adenomatous polyps of the sigmoid colon. Jpn J Cancer Res. 1994;85:479-484.
14. Bruce WR, Wolever TM, Giacca A. Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. Nutr Cancer. 2000;37:19-26.
15. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc. 2001;60:91-106.
16. Giovannucci E. Insulin and colon cancer. Cancer Causes Control. 1995;6:164-179.
17. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982;54:254-260.
18. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest. 1983;72:1150-1162.
19. Donahue RP, Abbott RD, Bloom E, Reed DM, Yano K. Central obesity and coronary heart disease in men. Lancet. 1987;1:821-824.
20. Tartter PI, Slater G, Papatestas AE, Aufses AH Jr. Cholesterol, weight, height, Quetelet's index, and colon cancer recurrence. J Surg Oncol. 1984;27:232-235.
21. Slattery ML, French TK, Egger MJ, Lyon JL. Diet and survival of patients with colon cancer in Utah: is there an association? Int J Epidemiol. 1989;18:792-797.
22. Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med. 1994;120:18-25.
23. Newman SC, Lees AW, Jenkins HJ. The effect of body mass index and oestrogen receptor level on survival of breast cancer patients. Int J Epidemiol. 1997;26:484-490.
24. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20:42-51.
25. Chlebowski RT, Aiello E, McTieman A. Weight loss in breast cancer patient management. J Clin Oncol. 2002;20:1128-1143.
26. Haller DG, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089 [abstract]. Proc Am Soc Clin Oncol. 1998;17:256a.
27. Haller DG, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: four-year results of INT-0089 [abstract]. Proc Am Soc Clin Oncol. 1997;16:940a.
28. McCollum AD, Catalano PJ, Haller DG, et al. Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002;94:1160-1167.
29. World Health Organization. Physical status: the use of interpretation of anthropometry: report of a WHO expert committee. World Health Organ Tech Rep Ser. 1995;854:1-452.
30. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
31. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
32. Cox D. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
33. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697-738.
34. Murphy TK, Calle EE, Rodriguez C, Khan HS, Thun MJ. Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol. 2000;152:847-854.
35. Wu AH, Paganini-Hill A, Ross RK, Henderson BE. Alcohol, physical activity and other risk factors for colorectal cancer: a prospective study. Br J Cancer. 1987;55:687-694.
36. Phillips RL, Snowdon DA. Dietary relationships with fatal colorectal cancer among Seventh-Day Adventists. J Natl Cancer Inst. 1985;74:307-317.
37. Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003;21:433-440.
38. Yamashita K, Mikami Y, Ikeda M, et al. Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers. Cancer Lett. 2002;188:231-236.
39. Tran TT, Medline A, Bruce WR. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev. 1996;5:1013-1015.
40. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst. 2000;92:1592-1600.
41. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999;91:1147-1154.
42. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999;91:620-625.
43. Ma J, Pollak M, Giovannucci E, et al. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm IGF Res. 2000;10(Suppl A):S28-S29.
44. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev. 2000;9:345-349.
45. Manousos O, Souglakos J, Bosetti C, et al. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer. 1999;83:15-17.
46. Rechler MM. Growth inhibition by insulin-like growth factor (IGF) binding protein-3 - what's IGF got to do with it? Endocrinology. 1997;138:2645-2647.
47. Poikonen P, Blomqvist C, Joensuu H. Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. Acta Oncol. 2001;40:67-71.
48. Georgiadis MS, Steinberg SM, Hankins LA, Ihde DC, Johnson BE. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst. 1995;87:361-366.
49. Kuczmarski RJ, Carroll MD, Flegal KM, Troiano RP. Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994). Obes Res. 1997;5:542-548.
50. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82:2123-2134.
51. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885-892.
52. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36:453-471.
53. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000;35:181-200.
54. Terry PD, Miller AB, Rohan TE. Obesity and colorectal cancer risk in women. Gut. 2002;51:191-194.
55. Giovannucci E. Obesity, gender, and colon cancer. Gut. 2002;51:147.
56. Havel PJ, Kasim-Karakas S, Dubuc GR, Mueller W, Phinney SD. Gender differences in plasma leptin concentrations. Nat Med. 1996;2:949-950.
57. Garaulet M, Perex-Llamas F, Fuente T, Zamora S, Tebar FJ. Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones. Eur J Endocrinol. 2000;143:657-666.
58. Mendoza-Nunez VM, Garcia-Sanchez A, Sanchez-Rodriguez M, Galvan-Duarte RE, Fonseca-Yerena ME. Overweight, waist circumference, age, gender, and insulin resistance as risk factors for hyperleptinemia. Obes Res. 2002;10:253-259.
59. Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology. 2001;121:79-90.
60. Attoub S, Noe V, Pirola L, et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J. 2000;14:2329-2338.
61. Balkau B, King H, Zimmet P, Raper LR. Factors associated with the development of diabetes in the Micronesian population of Nauru. Am J Epidemiol. 1985;122:594-605.
62. Lasky D, Becerra E, Boto W, Otim M, Ntambi J. Obesity and gender differences in the risk of type 2 diabetes mellitus in Uganda. Nutrition. 2002;18:417-421.
63. Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2002;155:65-71.
64. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92:1472-1489.
65. Crandall CJ. Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gend Based Med. 1999;8:1155-1166.
66. Fuchs CS, Mayer RJ. Adjuvant chemotherapy for colon and rectal cancer. Semin Radiat Oncol. 1993;3:29-41.